温州医科大学学报
溫州醫科大學學報
온주의과대학학보
Journal of Wenzhou Medical University
2014年
9期
637-640
,共4页
邬伟%陈晓红%杨景全%王小同
鄔偉%陳曉紅%楊景全%王小同
오위%진효홍%양경전%왕소동
骨髓间充质干细胞%阿尔茨海默病%人参皂苷Rg1%存活%分化%大鼠
骨髓間充質榦細胞%阿爾茨海默病%人參皂苷Rg1%存活%分化%大鼠
골수간충질간세포%아이자해묵병%인삼조감Rg1%존활%분화%대서
mesenchymal stem cell transplantation%Alzheimer’s disease%ginsenoside Rg1%survival%differ-entiation%rats
目的：探讨骨髓间充质干细胞（BMSCs）植入痴呆大鼠海马中的存活、分化情况及人参皂苷Rg1对其的影响及其机制。方法：雄性SD大鼠45只，采用随机数字法分为双侧穹窿海马伞（FF）切断模型组（模型组）：阿尔茨海默病（AD）模型；BMSCs移植治疗组（BMSCs组）：在模型制作2周后，每只大鼠接受1×106个BMSCs治疗；间充质干细胞联合人参皂苷Rg1治疗组（联合治疗组）：两者联合与BMSCs组同时进行。采用免疫组织化学法检测海马BrdU阳性细胞数，免疫组织化学双染法检测NSE、BrdU双染阳性细胞，RT-PCR技术检测海马神经生长因子（NGF）mRNA表达。结果：模型组在FF切断术后6周，联合治疗组BrdU阳性细胞数（34.2±5.4）较BMSCs组（10.3±4.3）多（P＜0.05）。联合治疗组海马NGF mRNA表达水平（1.13±0.21）较BMSCs组（0.75±0.12）有所升高（P＜0.05）。结论：人参皂苷Rg1能够促进植入AD模型大鼠海马中的BMSCs生存，其机制可能与人参皂苷Rg1能够提高AD模型大鼠海马组织NGF mRNA的表达有关。
目的：探討骨髓間充質榦細胞（BMSCs）植入癡呆大鼠海馬中的存活、分化情況及人參皂苷Rg1對其的影響及其機製。方法：雄性SD大鼠45隻，採用隨機數字法分為雙側穹窿海馬傘（FF）切斷模型組（模型組）：阿爾茨海默病（AD）模型；BMSCs移植治療組（BMSCs組）：在模型製作2週後，每隻大鼠接受1×106箇BMSCs治療；間充質榦細胞聯閤人參皂苷Rg1治療組（聯閤治療組）：兩者聯閤與BMSCs組同時進行。採用免疫組織化學法檢測海馬BrdU暘性細胞數，免疫組織化學雙染法檢測NSE、BrdU雙染暘性細胞，RT-PCR技術檢測海馬神經生長因子（NGF）mRNA錶達。結果：模型組在FF切斷術後6週，聯閤治療組BrdU暘性細胞數（34.2±5.4）較BMSCs組（10.3±4.3）多（P＜0.05）。聯閤治療組海馬NGF mRNA錶達水平（1.13±0.21）較BMSCs組（0.75±0.12）有所升高（P＜0.05）。結論：人參皂苷Rg1能夠促進植入AD模型大鼠海馬中的BMSCs生存，其機製可能與人參皂苷Rg1能夠提高AD模型大鼠海馬組織NGF mRNA的錶達有關。
목적：탐토골수간충질간세포（BMSCs）식입치태대서해마중적존활、분화정황급인삼조감Rg1대기적영향급기궤제。방법：웅성SD대서45지，채용수궤수자법분위쌍측궁륭해마산（FF）절단모형조（모형조）：아이자해묵병（AD）모형；BMSCs이식치료조（BMSCs조）：재모형제작2주후，매지대서접수1×106개BMSCs치료；간충질간세포연합인삼조감Rg1치료조（연합치료조）：량자연합여BMSCs조동시진행。채용면역조직화학법검측해마BrdU양성세포수，면역조직화학쌍염법검측NSE、BrdU쌍염양성세포，RT-PCR기술검측해마신경생장인자（NGF）mRNA표체。결과：모형조재FF절단술후6주，연합치료조BrdU양성세포수（34.2±5.4）교BMSCs조（10.3±4.3）다（P＜0.05）。연합치료조해마NGF mRNA표체수평（1.13±0.21）교BMSCs조（0.75±0.12）유소승고（P＜0.05）。결론：인삼조감Rg1능구촉진식입AD모형대서해마중적BMSCs생존，기궤제가능여인삼조감Rg1능구제고AD모형대서해마조직NGF mRNA적표체유관。
Objective:To explore the effect and mechanism of ginsenoside Rg1 on survival and differentia-tion of implanted BMSCs in dementia model rats. MethodForty ifve male SD rats were randomly divided into the FF transected model group (model group:ambi-hippocampal ifmbria-fornix transected), the bone marrow mesenchymal stem cells (BMSCs treatment group):Two weeks after the model-made, every rat received trans-plantation of BMSCs (10 μL, 1×106 cells) into hippocampus on both sides by Hamilton microinjector with ste-reotaxis, combining group (ginsenoside Rg1 combining BMSCs treatment group) received both transplantation of BMSCs and peritoneal infusion of ginsenoside Rg1 (Two weeks after the model-made, every rat received perito-neal infusion of ginsenoside Rg1 (5 mg/kg), one day a time, until a month). Survival and migration of implanted BMSCs were observed by immunohistochemistry staining. Differentiation of BMSCs was observed using immu-nohistochemistry double staining. In order to explore the mechanism of ginsenoside Rg1 increased the number of implanted BMSCs, RT-PCR technique was used to detect the change of NGF mRNA expression in hippocampus. ResultSix weeks after the model-made, The number of BrdU positive cells in hippocampus of combining treat-ment group (34.2±5.4) was more than those of simple BMSCs treatment group (10.3±4.3), difference was signiif-cant (P<0.05). The level of NGFmRNA expression in hippocampus of combining treatment group (1.13±0.21) was higher than that of BMSCs treatment group (0.75±0.12), difference was signiifcant. Conclusion:ginsenoside Rg1 is beneift to the survival of implanted BMSCs. Ginsenoside Rg1 may facilitate the survival of implanted BMSCs by up-regulating content of NGF mRNA in hippocampus.
